Protara Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Protara Therapeutics filed its 2023 10-K, detailing its financial status and stock information.</b>

AI Summary

Protara Therapeutics, Inc. (TARA) filed a Annual Report (10-K) with the SEC on March 13, 2024. Protara Therapeutics, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is registered in Delaware and its principal executive offices are located at 345 Park Avenue South, 3rd Floor, New York, NY 10010. Protara Therapeutics' common stock, par value $0.001 per share, is traded under the symbol TARA on The Nasdaq Capital Market. The company has not been a well-known seasoned issuer and is classified as a non-accelerated filer and a smaller reporting company. Protara Therapeutics has submitted all required reports for the preceding 12 months and has been subject to these filing requirements for the past 90 days.

Why It Matters

For investors and stakeholders tracking Protara Therapeutics, Inc., this filing contains several important signals. This filing provides a comprehensive overview of Protara Therapeutics' financial performance and operational status for the fiscal year 2023, crucial for investors to assess the company's health and future prospects. As a smaller reporting company and non-accelerated filer, this 10-K is essential for understanding Protara's regulatory compliance and its position within the market, especially for retail investors.

Risk Assessment

Risk Level: medium — Protara Therapeutics, Inc. shows moderate risk based on this filing. The company is a smaller reporting company and a non-accelerated filer, indicating a potentially less mature business with fewer resources compared to larger, accelerated filers, which can imply higher operational and financial risks.

Analyst Insight

Investors should review the detailed financial statements and risk factors within the 10-K to understand Protara Therapeutics' current financial health and potential challenges.

Key Numbers

• 20231231 — Fiscal Year End (Conformed Period of Report)
• 20240313 — Filing Date (Filed as of Date)
• 001-36694 — Commission File Number (SEC File Number)
• 204580525 — IRS Number (I.R.S. Employer Identification No.)
• $0.001 — Par Value (Common stock par value)

Key Players & Entities

• Protara Therapeutics, Inc. (company) — Filer name
• TARA (company) — Trading Symbol
• The Nasdaq Capital Market (company) — Exchange where stock is registered
• 345 Park Avenue South (company) — Principal Executive Offices
• New York (company) — City of Principal Executive Offices
• 10010 (company) — ZIP Code of Principal Executive Offices
• ArTara Therapeutics, Inc. (company) — Former Company Name
• PROTEON THERAPEUTICS INC (company) — Former Company Name

FAQ

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
• 2024-03-13: Filing Date — Date the 10-K report was officially filed with the SEC.

Key Financial Figures

• $0.001 — ich registered common stock, par value $0.001 per share TARA The Nasdaq Capital Marke
• $2.39 — sdaq Capital Market on June 30, 2023 of $2.39 per share. As of March 8, 2024, 11,43

Filing Documents

• f10k2023_protarathera.htm (10-K) — 1474KB
• f10k2023ex21-1_protarathera.htm (EX-21.1) — 4KB
• f10k2023ex23-1_protarathera.htm (EX-23.1) — 4KB
• f10k2023ex31-1_protarathera.htm (EX-31.1) — 11KB
• f10k2023ex31-2_protarathera.htm (EX-31.2) — 11KB
• f10k2023ex32-1_protarathera.htm (EX-32.1) — 6KB
• f10k2023ex97-1_protarathera.htm (EX-97.1) — 29KB
• img_001.jpg (GRAPHIC) — 66KB
• img_002.jpg (GRAPHIC) — 66KB
• img_003.jpg (GRAPHIC) — 85KB
• 0001213900-24-021982.txt (&nbsp;) — 7327KB
• tara-20231231.xsd (EX-101.SCH) — 69KB
• tara-20231231_cal.xml (EX-101.CAL) — 29KB
• tara-20231231_def.xml (EX-101.DEF) — 313KB
• tara-20231231_lab.xml (EX-101.LAB) — 546KB
• tara-20231231_pre.xml (EX-101.PRE) — 312KB
• f10k2023_protarathera_htm.xml (XML) — 707KB

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 31 Item 1B. Unresolved Staff Comments 60 Item 1C. Cybersecurity 60 Item 2.

Properties

Properties 61 Item 3.

Legal Proceedings

Legal Proceedings 61 Item 4. Mine Safety Disclosures 61 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 62 Item 6. Reserved 62 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 62 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 69 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 70 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 96 Item 9A.

Controls and Procedures

Controls and Procedures 96 Item 9B. Other Information 96 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 96 PART III Item 10. Directors, Executive Officers and Corporate Governance 97 Item 11.

Executive Compensation

Executive Compensation 97 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 97 Item 13. Certain Relationships and Related Transactions, and Director Independence 97 Item 14. Principal Accountant Fees and Services 97 PART IV Item 15. Exhibits and Financial Statement Schedules 98 Item 16. Form 10-K Summary 100 i PART I FORWARD-LOOKING This Annual Report on Form 10-K, including sections entitled " Business, " " Risk Factors, " and "Management's Discussion and Analysis of Financial Condition and Results of Operation s" and other materials accompanying this Annual Report on Form 10-K contain forward-looking statements or incorporate by reference forward-looking statements. Statements, other than statements of historical facts, contained in this document, including statements regarding our business, operations and financial performance and conditions, as well as our plans, objectives and expectations for our business operations and financial performance and condition, are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the

forward-looking statements. In some cases, you can identify these forward-looking statements by terminology such as

forward-looking statements. In some cases, you can identify these forward-looking statements by terminology such as "believes," "expects," "potential," "continues," "may," "will," "should," "seek," "approximately," "predict," "intend," "plans," "estimates," "anticipates" or the negative version of these terms or other comparable terminology. These

forward-looking statements include, but are not limited to, statements about

forward-looking statements include, but are not limited to, statements about: estimates regarding our financial performance, including future revenue, expenses and capital requirements; our expected cash position and ability to obtain financing in the future on satisfactory terms or at all; expectations regarding our plans to research, develop and commercialize our current and future product candidates, including TARA-002, and Intravenous, or IV, Choline Chloride; expectations regarding the safety and efficacy of our product candidates; expectations regarding the timing, costs and outcomes of our clinical trials; expectations regarding potential market size; expectations regarding the timing of the availability of data from our clinical trials; expectations regarding the clinical utility, potential benefits and market acceptance of our product candidates; expectations regarding our commercialization, marketing and manufacturing capabilities and strategy; the implementation of our business model, strategic plans for our business, product candidates and technology; expectations regarding our ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to our competitors and industry; our ability to acquire, license and invest in businesses, technologies, product candidates and products; our ability to remain listed on the Nasdaq Capital Market, or Nasdaq; the impact of government laws and regulations; costs and outcomes relating to any disputes, governmental inquiries or investigations, regulatory proceedings, legal proceedings or litigation; our ability to attract and retain key personnel to manage our business effectively; our ability to prevent system failures, data breaches or violations of data protection laws; the timing or likelihood of regulatory filings and approvals; our ability to protect our intellectual property position; and the impact

View Full Filing

View this 10-K filing on SEC EDGAR